

| | Injection Force (N) | G' | G'' | Shear Stress |
|--------------|---------------------|--------|-------|--------------|
| SYNOZ ONE® | 16.07 | 624.60 | 16.07 | 33.10 |
| Competitor 1 | 53.57 | 43.84 | 53.57 | 4.84 |
| Competitor 2 | 19.89 | 5.84 | 19.89 | 0.09 |

Comparative research¹ supports the pleasant features of SYNOZ ONE®. Including hardly any injection resistance, for a relaxed and easy application, and an extremely high Modulus of Rigidity and Viscosity, for excellent shock absorbing and friction reducing properties.

For all synovial joints

SYNOZ® and SYNOZ ONE® can be injected into all synovial joints, such as the knee, elbow and shoulder. Indications are, among others: gonarthritis, coxarthrosis, omarthritis, arthritis of the elbow, rhizarthritis and ankle arthritis.

Guaranteed by Kyeron

Instead of taking over bodily functions, our products activate the body and are fully resorbable. Together with our researchers we regularly succeed in launching innovative products, that merit their place in the field of medicine. Technically distinctive, with a sound clinical basis.

Kyeron is ISO 13485 certified, SYNOZ® and SYNOZ ONE® are CE certified medical devices and are manufactured according to GMP guidelines and ISO 13485 standards.

SYNOZ® and SYNOZ ONE® are registered trademarks.

1. Comparative study of SYNOZ ONE® and two other CE registered products, tested under equal conditions at the Italian Istituto Ricerche Applicate.



SYNOZ ONE® is a trademark of KYERON BV



+31 (0)53 851 0417 · info@kyeron.nl · www.kyeron.nl



BRIDGING MEDICAL GAPS



INJECTABLES TO RELIEVE (SYNOVIAL) JOINT PAIN

A damaged synovial joint causes discomfort. This pain and stiffness can significantly impact the patient's day-to-day life. That is why Kyeron developed SYNOZ® and SYNOZ ONE®.

The benefits

Our intra-articular injectables are minor medical interventions, often performed by a general practitioner. These treatments allow the patient to live without the limitations of pain. To stay mobile and enjoy everyday activities. And to postpone the (costly) replacement of a joint, such as the knee.

Why two different injectables?

Our SYNOZ-solutions have vital qualities in common. They are both manufactured in state of the art European facilities, according to the highest quality standards. They have ultra-high sterility, are water soluble and from bio fermentative origin (no chemicals or animal proteins). They also have essential differences. Their specific product features ensure one of them is the perfect fit for the individual patient's condition:

| SYNOZ® | SYNOZ ONE® |
|--------------------------------------|---|
| Multiple injections of 20 milligrams | One injection of 60 milligrams |
| Pain relief up to 6 months | Pain relief up to 12 months |
| Linear molecular structure | Cross linked molecular structure (patented) |

Multiple injections or just One

The SYNOZ-injections are administered once a week, up to five injections in total. This weekly treatment allows both doctor and patient to monitor the effects and progress. With SYNOZ ONE®, only one injection is administered; a very efficient solution in certain cases, and advantageous for both physician and patient. Both treatments are suitable for all synovial joints. The doctor or specialist can determine which procedure best meets the patient's needs.

Patented cross-linked molecules

Viscosity is key when treating a synovial joint for pain relieve. SYNOZ ONE® has the ultimate viscous capacity; the highest possible shock absorption and friction reduction. To reach that level of viscosity, we developed a patented cross-linked molecular composition. A dense hyaluronic acid network, interconnecting the individual hyaluronic acid molecules. The stabilization, achieved by a patented process, slows down the enzymatic degradation of the hyaluronic acid. The result is a superb, long-lasting cushion that protects the joint.



SYNOZ® is a trademark of KYERON BV

Cleanest in class

Kyeron is dedicated to creating the cleanest possible products. The first medical solutions we developed, were bio-materials for open surgery. The risks of infection, allergy and inflammation peak during such procedures. Therefore, we have taken unprecedented sterility and safety measures, from day one.

For SYNOZ® and SYNOZ ONE® this means:

- We sterilize our products with the terminal steam method. A 1.000 times safer approach compared to aseptic filling. This method guarantees inner and outer sterility of each syringe.
- We have a bioburden rate of zero. Our products do not contain detectable bacterial endotoxins.
- And, we only use European cleanroom facilities and European raw materials compliant with the most up to date applicable directives and regulation.

Ready-for-use

SYNOZ® and SYNOZ ONE® are ready-for-use. The prefilled syringe has a Luer-lock and convenient hardcover blister.

Significant pain reduction

SYNOZ® and SYNOZ ONE® are 100% clinically effective. But not every patient experiences the same degree of (stiffness/pain) relief. This can vary, due to their overall health and how they experience pain. We used the visual-analogue scale (VAS) to individually measure the significant and clinical pain reduction of 313 patients:

- 95% of patients were comfortable with the injections.
- 70% of patients had significant and clinically relevant pain reduction (VAS).
- 87% of physicians confirm the excellent efficacy of SYNOZ®.

SYNOZ®



Linear



High viscosity



Multiple injections



20 mg HA per syringe

SYNOZ ONE®



Crosslinked



Ultra-high viscosity



Single injection



60 mg HA per syringe

